Related references
Note: Only part of the references are listed.Significance of Glycemic Variability in Diabetes Mellitus
Yoshiki Kusunoki et al.
INTERNAL MEDICINE (2022)
Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-d-glucitol
Mana Ohigashi et al.
JOURNAL OF DIABETES INVESTIGATION (2021)
Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes
Yuusuke Watanabe et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Relationship between daily and visit-to-visit glycemic in patients with 2 diabetes
Tami Tsuchiya et al.
ENDOCRINE JOURNAL (2020)
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
Sebastian M. Heimburger et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
Taichi Nagahisa et al.
DIABETES THERAPY (2019)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Exenatide: pharmacokinetics, clinical use, and future directions
Filip K. Knop et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gender Difference of Gastric Emptying in Healthy Volunteers and Patients with Functional Dyspepsia
Hideki Mori et al.
DIGESTION (2017)
Influence of regular exercise on gastric emptying in healthy men: a pilot study
Juntaro Matsuzaki et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2016)
Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography
Masaru Kuroda et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Yoshifumi Saisho
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture
I. Teraguchi et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes
Junichi Matsubara et al.
CIRCULATION JOURNAL (2013)
Safety of exenatide once weekly for 52weeks in Japanese patients with type 2 diabetes mellitus
Yukiko Onishi et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
Linong Ji et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
C. Wysham et al.
DIABETIC MEDICINE (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes
Yoshifumi Saisho et al.
DIABETOLOGY INTERNATIONAL (2011)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
New and Improved Methods to Characterize Glycemic Variability Using Continuous Glucose Monitoring
David Rodbard
DIABETES TECHNOLOGY & THERAPEUTICS (2009)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg et al.
REGULATORY PEPTIDES (2008)
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic Hyperglycemia in patients with type 2 diabetes
L Monnier et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease
PO Bonetti et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
CMB Edwards et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2001)
Share Paper
